Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

Dr. Dietrich on Future Research Directions in Lung Cancer

September 3rd 2021

Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer. 

Dr. Van Rhee on Future Research Directions for CAR T-Cell Therapy in Multiple Myeloma

September 3rd 2021

Frits Van Rhee, MD, PhD

Frits van Rhee, MD, PhD, discusses future research directions with CAR T-cell therapy for the treatment of patients with multiple myeloma.

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas

September 3rd 2021

OncLive Staff

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.

Single-Agent Trastuzumab Yields Superior Health-Related QoL in HER2+ Breast Cancer

September 3rd 2021

Courtney Marabella

More detrimental effects on health-related quality of life were reported, and lasted for at least 12 months, with the combination of trastuzumab plus chemotherapy compared with trastuzumab alone in older patients with HER2-positive breast cancer, according to an analysis of the phase 3 RESPECT trial.

MYLOX-1 Trial Opens to Evaluate Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

September 3rd 2021

Jessica Hergert

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Devimistat Plus Gemcitabine/Cisplatin Moves to Phase 2 Setting in Frontline Biliary Tract Cancer

September 3rd 2021

Gina Mauro

Devimistat in combination with gemcitabine and cisplatin has moved into the phase 2 portion of a phase 1b/2 trial studying the regimen as a first-line treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

European Commission Expands Ravulizumab-cwvz Approval in Paroxysmal Nocturnal Hemoglobinuria With Pediatric Indication

September 3rd 2021

Gina Mauro

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

September 3rd 2021

Jorge J. Castillo, MD

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.

The Hamilton of Medicine

September 3rd 2021

Dawn Fallik

Most physician-scientists are intense, motivated and focused, but Keith T. Flaherty, MD, takes it to another level.

Dr. Herrera on the Utility of CAR T-Cell Therapy in Hematologic Cancers

September 3rd 2021

Alex Herrera, MD

Alex Herrera, MD, discusses the utility of CAR T cells in patients with hematologic cancers.

Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid Tumors

September 3rd 2021

Caroline Seymour

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

Dr. Harris on IMbrave150 Results With Atezolizumab/Bevacizumab in HCC

September 3rd 2021

William P. Harris, MD

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.

Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Advanced Neuroendocrine Tumors: VEGF-Targeted Therapies

September 3rd 2021

Diane Reidy-Lagunes, MD, Memorial Sloan-Kettering Cancer Center

Expert reflections on VEGF-targeted therapy’s role in the treatment of patients with neuroendocrine tumors.

Systemic Treatment Advances for Advanced HCC

September 3rd 2021

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

See All News